Proxygen Advances in Induced Proximity Therapeutics with New Programs

Proxygen GmbH, a biotechnology firm based in Vienna, has announced the expansion of its platform beyond targeted protein degradation. The company is focusing on the development of next-generation induced proximity therapeutics. This advancement includes two lead programs, p300 and CDK12, that are moving towards clinical development and address various cancer types.

Induced proximity drugs utilize the cell’s machinery by bringing proteins together to influence disease biology. This approach has the potential to target mechanisms beyond traditional pharmacology. Proxygen's CEO, Bernd Boidol, emphasized the power of this paradigm in drug discovery.

The p300 program aims to degrade a key epigenetic regulator involved in multiple cancers, while the CDK12 program targets HER2-driven cancers and tumors affecting the central nervous system. Chief Scientific Officer Chiara Conti highlighted the company's focus on advancing these programs over the next 12 to 18 months.